Research programme: viral therapeutics - Genekam
Alternative Names: Zika virus therapeuticsLatest Information Update: 28 Sep 2020
At a glance
- Originator Genekam Biotechnology
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ebola virus infections; Flavivirus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Zika virus infection
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Ebola-virus-infections in Germany
- 28 Sep 2020 No recent reports of development identified for research development in Flavivirus-infections in Germany
- 28 Sep 2020 No recent reports of development identified for research development in Influenza-virus-infections in Germany
Development Overview
Introduction
Genekam is developing therapeutic molecules for the treatment of various viral diseases including zika virus infection, influenza, Ebola, Middle East respiratory syndrome coronavirus (MERS) and mosquito borne flaviviruses. Currently, detection of Zika virus is the only option available for the prevention of the infection. The Zika virus infection generally causes mild or no symptoms. The symptoms if caused, are a very mild form of dengue fever. Zika can also spread from a pregnant woman to her fetus, which may result in microcephaly in the newborn. Early research of the therapeutic molecule for the Zika virus infection is underway in Germany.
As at September 2020, no recent reports of development had been identified for research development in Ebola-virus-infections in Germany, research development in Flavivirus-infections in Germany, research development in Influenza-virus-infections in Germany, research development in Middle-East-respiratory-syndrome-coronavirus in Germany, research development in Zika-virus-infection in Germany.
Key Development Milestones
In August 2016, Genekam annouced that the therapeutic molecule developed against Zika virus, inhibits the Zika virus infection and presumably is non-toxic. Additional studies are planned for the therapeutic molecule prior to human trials [1] .
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
WHO ATC code
J05A (Direct acting antivirals)
-
EPhMRA code
J5B (Antivirals, excluding anti-HIV products)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Ebola virus infections | - | - | No development reported (Research) | Germany | unspecified / unspecified | 28 Sep 2020 | |
| Flavivirus infections | - | - | No development reported (Research) | Germany | unspecified / unspecified | 28 Sep 2020 | |
| Influenza virus infections | - | - | No development reported (Research) | Germany | unspecified / unspecified | 28 Sep 2020 | |
| Middle East respiratory syndrome coronavirus | - | - | No development reported (Research) | Germany | unspecified / unspecified | 28 Sep 2020 | |
| Zika virus infection | - | - | No development reported (Research) | Germany | unspecified / unspecified | 28 Sep 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Genekam Biotechnology | Originator | Germany |
| Genekam Biotechnology | Owner | Germany |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Sep 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Ebola-virus-infections in Germany Updated 28 Sep 2020 |
| 28 Sep 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Flavivirus-infections in Germany Updated 28 Sep 2020 |
| 28 Sep 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Influenza-virus-infections in Germany Updated 28 Sep 2020 |
| 28 Sep 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Middle-East-respiratory-syndrome-coronavirus in Germany Updated 28 Sep 2020 |
| 28 Sep 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection in Germany Updated 28 Sep 2020 |
| 19 Aug 2016 | Phase Change | Early research in Ebola virus infections in Germany (unspecified route) [1] Updated 29 Aug 2016 |
| 19 Aug 2016 | Phase Change | Early research in Flavivirus infections in Germany (unspecified route) [1] Updated 29 Aug 2016 |
| 19 Aug 2016 | Phase Change | Early research in Influenza virus infections in Germany (unspecified route) [1] Updated 29 Aug 2016 |
| 19 Aug 2016 | Phase Change | Early research in Middle East respiratory syndrome coronavirus in Germany (unspecified route) [1] Updated 29 Aug 2016 |
| 19 Aug 2016 | Phase Change | Early research in Zika virus infection in Germany (unspecified route) [1] Updated 29 Aug 2016 |
References
-
World Innovation and Hope: First Therapeutic Molecule Candidate of Genekam Against Zika Viruses.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG